Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Influenza-immune-globulin-Emergent-BioSolutions (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza A virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Emergent BioSolutions
  • Most Recent Events

    • 18 Jun 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
    • 18 Jun 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2019.
    • 03 May 2018 According to an Emergent BioSolutions media release, this trial will continue to enrol patients through the next influenza season and is expected to be completed in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top